DC Treatment | TLR specificity | No Vaccine S.I. | Plus Vaccine S.I. |
---|---|---|---|
None | Â | - | - |
+ LPS | 4 | 4.1 | 4.0 |
+ Pam3CSK4 | 2 | 3.0 | 5.6 |
+ Flagellin | 5 | 2.4 | 4.8 |
+ MALP-2 | 2, 6 | 3.0 | 5.6 |
+ Poly IC | 3 | Â | Â |
(Fig. 2a-2b) | Â | 3.6 | 6.0 |
Fig. 2c | Â | 2.4 | 3.8 |
+ Loxoribine | 7 | 1.25 | 4.0 |
+ R-848 | 7, 8 | 2.39 | 1.85 |
(Fig. 2c) | Â | Â | Â |
+ Poly IC + R-848 | 3, 7, 8 | NT | 1.95 |
(Fig. 2c) | Â | Â | Â |